Tongyuan Kang Medicine-B (02410.HK) works together with Qilu to advance the development, production, and commercialization of the new drug TY-9591, with the latter investing 400 million yuan in strategic equity.

Zhixun Finance News APP, Tongyuan Kang Medicine-B (02410.HK) announced that on July 21, 2026 (after trading hours), the company entered into a license and cooperation agreement along with a supply and commercialization agreement with Qilu or its designated affiliates to collaborate on the development, production, and commercialization of the collaborative raw material medicine (TY-9591 raw material medicine) in China, aiming to advance the development, production, and commercialization of innovative drugs. Under the license and cooperation agreement, the company will receive a total of approximately RMB 700 million in upfront payments, including approximately RMB 400 million from the subscription agreement, and milestone payments related to the regulatory approval and indication expansion of TY-9591, up to a cumulative total of RMB 20.6 billion.